Estimated Long-Term Survival With Eplerenone

• Published in: Journal of the American College of Cardiology Vol. 73; no. 18; pp. 2357 - 2359
• Main Authors: Stienen, Susan, Ferreira, João Pedro, Vincent, John, Busselen, Martijn, Li, Benjamin, McMurray, John J.V., Pitt, Bertram, Girerd, Nicolas, Rossignol, Patrick, Zannad, Faiez
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 14.05.2019; Elsevier Limited
• Subjects: Age; Cardiology; Clinical medicine; Congestive heart failure; Eplerenone - therapeutic use; Female; Health Services Misuse - statistics & numerical data; Heart; Heart attacks; Heart failure; Heart Failure - drug therapy; Heart Failure - mortality; Heart Failure - physiopathology; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mineralocorticoid Receptor Antagonists - therapeutic use; Myocardial infarction; Myocardial Infarction - drug therapy; Myocardial Infarction - physiopathology; Patients; Randomized Controlled Trials as Topic; Stroke Volume - drug effects; Survival; Time; Ventricle; Ventricular Dysfunction, Left - diagnosis; Ventricular Dysfunction, Left - etiology; New York; United States > US
• ISSN: 0735-1097; 1558-3597
• DOI: 10.1016/j.jacc.2019.02.043

Despite Class I recommendations in current American College of Cardiology/American Heart Association guidelines for heart failure (HF) with reduced ejection fraction (HFrEF) and acute myocardial infarction (AMI) with left ventricular systolic dysfunction (LVSD) and/or HF (1), mineralocorticoid receptor antagonists (MRAs) are substantially underused in clinical practice (2). By reporting the estimated years of event-free survival with eplerenone versus placebo in the EMPHASIS-HF (A Comparison Of Outcomes In Patients In New York Heart Association [NYHA] Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines) study (3) and EPHESUS (Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) (4), we aimed to provide additional, easily understandable information to help increase MRA use in clinical practice. [...]our findings suggest that eplerenone use in HFrEF and AMI complicated by LVSD and/or HF may extend event-free survival up to 3 and 2 years, respectively.